PHOEBUS - A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications (PHOEBUS)

Research summary

Allogeneic hematopoietic cell transplantation (alloHCT) is a well-established therapy for different lifethreatening hematologic malignancies. The use of alloHCT is constantly increasing, with nearly 20 000 transplantations reported to the European Society for Blood and Marrow Transplantation (EBMT) per year. However, this treatment is limited by high morbidity and mortality, mainly related to relapse, infection, graft-versus-host disease (GvHD), and conditioning-related toxicity. Therefore, overall survival (OS) and GvHD-free, relapse-free survival (GRFS) after alloHCT, remain low, around 60% and 30% at one year. Over the last few years, comprehensive analysis of gut microbiota composition revealed the that use of broad-spectrum antibiotics induced loss of bacterial diversity after alloHCT, associated with an increased GvHD-related mortality This randomized, placebo-controlled phase IIb study (PHOEBUS trial) aims to evaluate the activity of MaaT033 to improve survival through the prevention of transplant-related complications in eligible alloHCT patients.

Principal Investigator

Kirsty Sharplin

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1009083